PTC Therapeutics. has been granted a patent for a method to treat pancreatic cancer, specifically pancreatic ductal adenocarcinoma, using a tubulin polymerization inhibitor. The method involves administering a specific compound, either alone or with other chemotherapy agents, to affected patients. GlobalData’s report on PTC Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights PTC Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on PTC Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. PTC Therapeutics's grant share as of June 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Method for treating pancreatic cancer using tubulin inhibitors

Source: United States Patent and Trademark Office (USPTO). Credit: PTC Therapeutics Inc

A recently granted patent (US12023335B2) outlines a method for treating pancreatic cancer, specifically pancreatic ductal adenocarcinoma, through the administration of a compound identified as 5-fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazol-1-yl)-N4-[4-(trifluoromethyl)phenyl]pyrimidine-4,6-diamine. The claims emphasize the use of this compound, or its pharmaceutically acceptable salts, in an effective amount to achieve specific plasma concentration levels over a 24-hour period. The patent details various ranges for mean plasma concentrations, indicating a focus on optimizing dosage for therapeutic efficacy.

The claims further specify that the effective amount of the compound should result in plasma concentrations ranging from approximately 3 hr·µg/ml to 70 hr·µg/ml, with additional claims narrowing this range to 60 hr·µg/ml, 50 hr·µg/ml, 40 hr·µg/ml, and 30 hr·µg/ml. This structured approach to dosage aims to ensure that the treatment is both effective and safe for patients suffering from this aggressive form of cancer. The patent underscores the potential of this compound as a targeted therapeutic option in the ongoing fight against pancreatic cancer.

To know more about GlobalData’s detailed insights on PTC Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies